Literature DB >> 2719851

Histomorphometric analysis of bone in idiopathic hypercalciuria before and after treatment with thiazide.

T Steiniche1, L Mosekilde, M S Christensen, F Melsen.   

Abstract

Twenty-seven normocalcemic patients aged 11-69 yrs with recurrent renal stone formation and idiopathic hypercalciuria were studied before and after treatment with hydrochlorthiazide (TD) 50 mg twice a day for 6 months. Hypercalciuria was defined as a 24 h renal calcium excretion of more than 7.5 mmol for males and 6.3 mmol for females. Quantitative histomorphometric analysis of iliac crest bone biopsies were performed before and after treatment. TD treatment increased the adjusted serum calcium level (p less than 0.01), whereas no significant effects on the serum levels of phosphorous, alkaline phosphatase or iPTH were found. The urinary calcium/creatinine ratio decreased (p less than 0.01) during TD treatment, whereas no change in the urinary phosphorous/creatinine ratio was found. The histomorphometric analysis revealed a reduction in the extent of eroded surfaces (p less than 0.05) and bone formation rate (p less than 0.05) as well as a decrease in the osteoid thickness (p less than 0.05) during TD treatment. No effect on the trabecular bone volume was found. A reduction in the activation frequency of new remodeling sites and thereby a reduced bone turnover during TD treatment can explain the observed histomorphometric changes. The decrease in osteoid thickness may be related to the increased serum calcium concentration leading to better conditions for mineralization.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2719851     DOI: 10.1111/j.1699-0463.1989.tb00792.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  8 in total

1.  Mitogenic action of hydrochlorothiazide on human osteoblasts in vitro: requirement for platelet-derived growth factor.

Authors:  K H Lau; X D Song; M Ochi; J E Wergedal
Journal:  Calcif Tissue Int       Date:  1996-12       Impact factor: 4.333

2.  Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats.

Authors:  Nancy S Krieger; John R Asplin; Ignacio Granja; Felix M Ramos; Courtney Flotteron; Luojing Chen; Tong Tong Wu; Marc D Grynpas; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2019-05-17       Impact factor: 10.121

Review 3.  Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

Authors:  Khashayar Sakhaee; Naim M Maalouf; Rajiv Kumar; Andreas Pasch; Orson W Moe
Journal:  Kidney Int       Date:  2010-12-01       Impact factor: 10.612

4.  Chlorthalidone vs. potassium citrate in a model of hypercalciuria: differential effects on stone and bone.

Authors:  Gianmarco Lombardi; Pietro Manuel Ferraro; Giovanni Gambaro
Journal:  Ann Transl Med       Date:  2019-09

5.  Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming rats.

Authors:  David A Bushinsky; Thomas Willett; John R Asplin; Christopher Culbertson; Sara P Y Che; Marc Grynpas
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

6.  The relation between bone and stone formation.

Authors:  Nancy S Krieger; David A Bushinsky
Journal:  Calcif Tissue Int       Date:  2012-12-18       Impact factor: 4.333

7.  Chlorthalidone with potassium citrate decreases calcium oxalate stones and increases bone quality in genetic hypercalciuric stone-forming rats.

Authors:  Nancy S Krieger; John Asplin; Ignacio Granja; Luojing Chen; Daiana Spataru; Tong Tong Wu; Marc Grynpas; David A Bushinsky
Journal:  Kidney Int       Date:  2021-01-05       Impact factor: 10.612

Review 8.  The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density.

Authors:  Anna C van der Burgh; Catherine E de Keyser; M Carola Zillikens; Bruno H Stricker
Journal:  Drugs       Date:  2021-11-01       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.